Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

aTYR PHARMA (ATYR) Return on Equity (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Return on Equity for 7 consecutive years, with 1.05% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity fell 4.0% year-over-year to 1.05%, compared with a TTM value of 1.05% through Dec 2025, down 4.0%, and an annual FY2025 reading of 1.13%, down 28.0% over the prior year.
  • Return on Equity was 1.05% for Q4 2025 at aTYR PHARMA, down from 1.02% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.3% in Q4 2021 and bottomed at 1.05% in Q4 2025.
  • Average Return on Equity over 5 years is 0.66%, with a median of 0.62% recorded in 2022.
  • The sharpest move saw Return on Equity increased 24bps in 2022, then plummeted -47bps in 2024.
  • Year by year, Return on Equity stood at 0.3% in 2021, then plummeted by -108bps to 0.63% in 2022, then increased by 7bps to 0.58% in 2023, then tumbled by -73bps to 1.01% in 2024, then decreased by -4bps to 1.05% in 2025.
  • Business Quant data shows Return on Equity for ATYR at 1.05% in Q4 2025, 1.02% in Q3 2025, and 0.94% in Q2 2025.